CDKN2A and alpha thalassemia spectrum: The main molecular markers investigated for glioma diagnosis include Isocitrate Dehydrogenase (IDH) mutations, 1p19q deletion, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation statutes, Telomerase Reverse Transcriptase (TERT) mutations, Alpha-Thalassemia/mental Retardation syndrome X-linked (ATRX), CDKN2A/B deletion, EGFR (Epidermal growth factor receptor) amplification, TP53, and BRAF [14] (Figure 3).